Linda M. Liau, M.D., Ph.D., MBA

Liau leads a translational research program focused on developing and testing immune-based treatments for glioblastoma and other primary brain tumors, with an emphasis on dendritic cell vaccines, gene therapy and immunomodulation. A leader in neuro-oncology and translational neuroscience, she developed one of the first personalized dendritic cell vaccines for glioblastoma and has continued to advance immunomodulatory strategies that harness the immune system to target aggressive brain cancers. Her work laid the foundation for a series of clinical trials testing next-generation cellular and gene-based therapies in patients with gliomas.

Liau’s lab also investigates the molecular mechanisms that drive tumor development and resistance, with a focus on isocitrate dehydrogenase, or IDH, mutations in gliomas and the progression of meningiomas. By integrating insights from tumor immunology, molecular biology and neurosurgery, her team aims to uncover new therapeutic targets and improve outcomes for patients with brain tumors that have historically had limited treatment options.

Her clinical expertise is in brain tumor surgery, intraoperative brain mapping and minimally invasive techniques for gliomas, meningiomas and brain metastases.